Is there an association between vasomotor symptoms and both low bone density and cardiovascular risk?

Menopause

Volumn 16, Issue 2, 2009, Pages 219-223

  Pinkerton, JoAnn V ^a   Stovall, Dale W ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; ESTRADIOL; ESTROGEN; FOLLITROPIN; GROWTH HORMONE; HYDROCORTISONE; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT;

ANXIETY DISORDER; BONE DENSITY; CARDIOVASCULAR RISK; CLIMACTERIUM; CLINICAL FEATURE; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; EDITORIAL; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYDROCORTISONE BLOOD LEVEL; MORBIDITY; OSTEOLYSIS; OSTEOPOROSIS; OVARIAN RESERVE; PATHOGENESIS; PREMENOPAUSE; QUALITY OF LIFE; VASOMOTOR DISORDER;

BONE DENSITY; CARDIOVASCULAR DISEASES; HOT FLASHES; HUMANS; OSTEOPOROSIS; PREMENOPAUSE; QUALITY OF LIFE; RISK FACTORS; VASOMOTOR SYSTEM;

EID: 67649303421     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318199404a     Document Type: Editorial

References (51)

1. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet 2002;360:1851-1861.
2. Freeman EW, Sammel MD, Liu L, Gracia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62-70.
3. Freeman EW, Sammel MD, Lin H, Gracia CR, Kapoor S, Ferdousi T. The role of anxiety and hormonal changes in menopausal hot flashes. Menopause 2005;12:258-266.
4. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 2003;101:264-272.
5. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47.
6. Lobo RA, Belisle S, Creasman WT, et al. Should symptomatic menopausal women be offered hormone therapy? MedGenMed 2006; 8:40.
7. Huang AJ, Grady D, Jacoby VL, Blackwell TL, Bauer DC, Sawaya GF. Persistent hot flushes in older postmenopausal women. Arch Intern Med 2008;168:840-846.
8. Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 1998;70:332-337.
9. Aksel S, Schomberg DW, Tyrey L, Hammond CB. Vasomotor symptoms, serum estrogens, and gonadotropin levels in surgical menopause. Am J Obstet Gynecol 1976; 126:165-169.
10. Freedman RR, Dinsay R. Clonidine raises the sweating threshold in symptomatic but not in asymptomatic postmenopausal women. Fertil Steril 2000;74:20-23.
11. Gambone J, Meldrum DR, Laufer L, Chang RJ, Lu JK, Judd HL. Further delineation of hypothalamic dysfunction responsible for menopausal hot flashes. J Clin Endocrinol Metab 1984;59:1097-1102.
12. Gordon DL, Emanuele MA. Hot flashes in patients with hypogonadism and low serum gonadotropin levels. Endocr Pract 2003;9:119-123.
13. Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005;23:117-125.
14. Meldrum DR, Defazio JD, Erlik Y, et al. Pituitary hormones during the menopausal hot flash. Obstet Gynecol 1984;64:752-756.
15. Casper RF, Yen SS. Menopausal flushes: effect of pituitary gonadotropin desensitization by a potent luteinizing hormone-releasing factor agonist. J Clin Endocrinol Metab 1981;53:1056-1058.
16. Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol (Oxf) 1985;22: 293-312.
17. Hammar M, Ekblad S, Lonnberg B, Berg G, Lindgren R, Wyon Y. Postmenopausal women without previous or current vasomotor symptoms do not flush after abruptly abandoning estrogen replacement therapy. Maturitas 1999;31:117-122.
18. Freeman EW, Sammel MD, Rinaudo PJ, Sheng L. Premenstrual syndrome as a predictor of menopausal symptoms. Obstet Gynecol 2004; 103:960-966.
19. Weiss G, Skurnick JH, Goldsmith LT, Santoro NF, Park SJ. Menopause and hypothalamic-pituitary sensitivity to estrogen. JAMA 2004; 292:2991-2996.
20. Crandall CJ, Crawford SL, Gold EB. Vasomotor symptom prevalence is associated with polymorphisms in sex steroid-metabolizing enzymes and receptors. Am J Med 2006;119:S52-S60.
21. Woods NF, Mitchell ES, Tao Y, Viernes HM, Stapleton PL, Farin FM. Polymorphisms in the estrogen synthesis and metabolism pathways and symptoms during the menopausal transition: observations from the Seattle Midlife Women's Health Study. Menopause 2006;13: 902-910.
22. Freedman RR, Benton MD, Genik RJ 2nd, Graydon FX. Cortical activation during menopausal hot flashes. Fertil Steril 2006;85:674-678.
23. Carpenter JS, Andrykowski MA, Freedman RR, Munn R. Feasibility and psychometrics of an ambulatory hot flash monitoring device. Menopause 1999;6:209-215.
24. Freedman RR. Laboratory and ambulatory monitoring of menopausal hot flashes. Psychophysiology 1989;26:573-579.
25. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: labeling guidance for noncontraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar and vaginal atrophy symptoms - prescribing information for health care providers and patient labeling [revision 1]. Rockville, MD: Division of Drug Information, Center for Drug Evaluation and Research (CDER), 2004;1-2.
26. Miller HG, Li RM. Measuring hot flashes: summary of a National Institutes of Health workshop. Mayo Clin Proc 2004;79:777-781.
27. Pal L, Bevilacqua K, Zeitlian G, Shu J, Santoro N. Implications of diminished ovarian reserve (DOR) extend well beyond reproductive concerns. Menopause 2008;15:1086-1094.
28. Pal L, Norian J, Zeitlian G, Bevilacqua K, Freeman R, Santoro N. Vasomotor symptoms in infertile premenopausal women: a hitherto unappreciated risk for low bone mineral density. Fertil Steril 2008;90: 1626-1634.
29. Lee SJ, Kanis JA. An association between osteoporosis and premenstrual symptoms and postmenopausal symptoms. Bone Miner 1994;24: 127-134.
30. Salamone LM, Gregg E, Wolf RL, et al. Are menopausal symptoms associated with bone mineral density and changes in bone mineral density in premenopausal women? Maturitas 1998;29:179-187.
31. Naessen T, Persson I, Ljunghall S, Bergstrom R. Women with climacteric symptoms: a target group for prevention of rapid bone loss and osteoporosis. Osteoporos Int 1992;2:225-231.
32. von Muhlen DG, Soroko S, Kritz-Silverstein D, Barrett-Connor E. Vasomotor symptoms are not associated with reduced bone mass in postmenopausal women: the Rancho Bernardo Study. J Womens Health Gend Based Med 2000;9:505-511.
33. Scoutellas V, O'Neill TW, Lunt M, Reeve J, Silman AJ. Does the presence of postmenopausal symptoms influence susceptibility to vertebral deformity? European Vertebral Osteoporosis Study (EVOS) group. Maturitas 1999;32:179-187.
34. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Public Health 2006;96:1226-1235.
35. Vural F, Vural B, Yucesoy I, Badur S. Ovarian aging and bone metabolism in menstruating women aged 35-50 years. Maturitas 2005;52:147-153.
36. Gast GC, Grobbee DE, Pop VJ, et al. Vasomotor symptoms are associated with a lower bone mineral density. Menopause 2009;16:231-238.
37. Crandall CJ, Zheng Y, Crawford SL, et al. Presence of vasomotor symptoms is associated with lower bone mineral density: a longitudinal analysis. Menopause 2009; 16:239-246.
38. Riggs BL. Endocrine causes of age-related bone loss and osteoporosis. Novartis Found Symp 2002;242:247, 59; discussion 260-4.
39. Heshmati HM, Khosla S, Robins SP, O'Fallon WM, Melton LJ 3rd, Riggs BL. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002;17:172-178.
40. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in post- menopausal women with hysterectomy: results from the Women's Health Initiative randomized trial. J Bone Miner Res 2006;21:817-828.
41. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. The writing group for the PEPI (see comment). JAMA 1996;276:1389-1396.
42. Sowers MR, Jannausch M, McConnell D, et al. Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab 2006;91:1261-1267.
43. Sun L, Peng Y, Sharrow AC, et al. FSH directly regulates bone mass. Cell 2006; 125:247-260.
44. Iqbal J, Sun L, Kumar TR, Blair HC, Zaidi M. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci U S A 2006; 103: 14925-14930.
45. Martin TJ, Gaddy D. Bone loss goes beyond estrogen. Nat Med 2006;12:612-613.
46. Baron R. FSH versus estrogen: who's guilty of breaking bones? Cell Metab 2006;3:302-305.
47. Devleta B, Adem B, Senada S. Hypergonadotropic amenorrhea and bone density: new approach to an old problem. J Bone Miner Metab 2004;22:360-364.
48. Ishida Y, Kawai S. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi Osteoporosis Prevention Study. Am J Med 2004;117:549-555.
49. van der Schouw YT, Grobbee DE. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. Eur Heart J 2005;26: 1358-1361.
50. Gast GC, Grobbee DE, Pop VJ, et al. Menopausal complaints are associated with cardiovascular risk factors. Hypertension 2008;51:1492-1498.
51. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study. Circulation 2008; 118:1234-1240.